MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MBX Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$52.48+2.87 (+5.79%)
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
55M of 48M shares
Institutional holders
173
39 new, 20 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
1 buys · 5 sales
Net sold $2.21M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC | 5,322,885 | 11.20% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick J. Heron | 5,243,421 | 11.70% | 13D (active) amendment | Aug 6, 2026 |
| Wellington Group Holdings LLP | 4,977,523 | 10.50% | 13G (passive) amendment | Jun 30, 2026 |
| Wellington Investment Advisors Holdings LLP | 4,823,336 | 10.80% | 13G (passive) amendment | Sep 30, 2025 |
| Edward T. Mathers | 3,619,474 | 8.10% | 13D (active) amendment | Nov 6, 2025 |
| Orbimed Advisors LLC | 3,074,853 | 6.40% | 13D (active) amendment | Aug 6, 2026 |
| BlackRock, Inc. | 2,628,181 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Paradigm BioCapital Advisors LP | 2,493,015 | 5.20% | 13G (passive) | Jun 16, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MBX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,652,013 | 13.81% | $367.19M | – | 8.00% |
| FMR LLC | 5,322,885 | 11.05% | $293.82M | +2,386,201 | 0.01% |
| Wellington Management Group Llp | 4,977,523 | 10.34% | $274.76M | +1,785,699 | 0.05% |
| NEA Management Company, LLC | 3,614,486 | 7.51% | $199.52M | – | 12.56% |
| Orbimed Advisors LLC | 3,428,736 | 7.12% | $189.27M | −209,151 | 3.51% |
| BlackRock, Inc. | 3,323,672 | 6.90% | $183.47M | +382,266 | 0.00% |
| Paradigm Biocapital Advisors LP | 2,508,015 | 5.21% | $138.44M | New | 2.59% |
| NVP Associates, LLC | 2,136,335 | 4.44% | $117.93M | – | 35.93% |
| Deep Track Capital, LP | 1,732,569 | 3.60% | $95.64M | −1,025,000 | 1.39% |
| Polar Capital Holdings Plc | 1,608,514 | 3.34% | $88.79M | −13,672 | 0.21% |
| Vanguard Capital Management LLC | 1,477,388 | 3.07% | $81.55M | −204 | 0.00% |
| Aaron Wealth Advisors LLC | 1,167,799 | 2.42% | $64.46M | −377 | 3.27% |
| Driehaus Capital Management LLC | 1,056,579 | 2.19% | $58.32M | +38,367 | 0.34% |
| Kynam Capital Management, LP | 934,799 | 1.94% | $51.60M | – | 2.85% |
| Woodline Partners LP | 900,092 | 1.87% | $49.69M | +29 | 0.15% |
| Eventide Asset Management, LLC | 873,492 | 1.81% | $48.22M | −16,508 | 0.64% |
| State Street Corp | 864,466 | 1.79% | $47.72M | +77,258 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 814,807 | 1.69% | $44.98K | −214,200 | 0.00% |
| Parkman Healthcare Partners LLC | 800,173 | 1.66% | $44.17M | +136 | 4.52% |
| Geode Capital Management, LLC | 773,072 | 1.61% | $42.68M | +102,687 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 173 | 55M | 100.0% | 39 / 64 | 49 / 20 | 10M | 7M |
| Q1 2026 | 157 | 53M | 100.0% | 39 / 43 | 47 / 18 | 12M | 6M |
| Q4 2025 | 138 | 48M | 100.0% | 45 / 53 | 25 / 25 | 7M | 7M |
| Q3 2025 | 118 | 48M | 99.2% | 39 / 30 | 29 / 9 | 15M | 4M |
| Q2 2025 | 88 | 37M | 76.6% | 21 / 40 | 14 / 12 | 5M | 4M |
| Q1 2025 | 79 | 36M | 74.1% | 27 / 24 | 15 / 10 | 4M | 1M |
| Q4 2024 | 63 | 33M | 68.4% | 33 / 11 | 8 / 15 | 3M | 1M |
| Q3 2024 | 45 | 30M | 62.9% | 45 / 0 | 0 / 0 | 30M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MBX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,135,375 | 2.36% | $62.67M | 0.00% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 873,492 | 1.81% | $48.22M | 2.70% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 817,600 | 1.70% | $53.90M | 2.45% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 796,629 | 1.65% | $43.97M | 0.05% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 636,100 | 1.32% | $41.94M | 0.57% | Jul 31, 2026 |
| Select Health Care Portfolio | 600,000 | 1.25% | $18.88M | 0.33% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 586,309 | 1.22% | $32.36M | 0.27% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 416,420 | 0.86% | $27.45M | 0.31% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 365,200 | 0.76% | $24.08M | 0.51% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 339,492 | 0.70% | $22.38M | 0.07% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 333,350 | 0.69% | $10.49M | 0.18% | May 29, 2026 |
| Fidelity Advisor Health Care Fund | 328,000 | 0.68% | $21.63M | 0.69% | Jul 31, 2026 |
| Fidelity Fund | 321,100 | 0.67% | $17.72M | 0.20% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 305,998 | 0.64% | $16.89M | 0.02% | Jun 30, 2026 |
| VIP Contrafund Portfolio | 286,900 | 0.60% | $15.84M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven L. Hoerter | President and CEO, Director | 102,938 | 0.21% | Aug 4, 2026 |
| P. Kent Hawryluk | President & CEO, Director | 1,214,444 | 2.52% | May 8, 2026 |
| Salomon Azoulay | Chief Medical Officer | 14,399 | 0.03% | Aug 5, 2026 |
| John W. Smither | Chief Financial Officer | 28,000 | 0.06% | Aug 4, 2026 |
| Richard Bartram | Chief Financial Officer | 15,000 | 0.03% | Feb 3, 2026 |
| Patrick J. Heron | Director, 10% owner | 3,927,774 | 8.16% | Jun 5, 2026 |
| Laurie Stelzer | Director | – | – | Jun 5, 2026 |
| Ora H. Pescovitz | Director | 24,329 | 0.05% | Jun 5, 2026 |
| Tiba Aynechi | Director | 1,386,335 | 2.88% | Jun 5, 2026 |
| Steven Ryder | Director | – | – | Jun 5, 2026 |
| Edward T. Mathers | Director | 3,614,486 | 7.51% | Jun 5, 2026 |
| James M. Cornelius | Director | 102,082 | 0.21% | Jun 6, 2025 |
| Carl L. Gordon | Director, 10% owner | 747,887 | 1.55% | Feb 19, 2025 |
| Advisors Llc Orbimed | Director, 10% owner | 3,812,215 | 7.92% | Feb 19, 2025 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | – | – | Feb 19, 2025 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 3,255,000 | 6.76% | Feb 19, 2025 |
| Fhmls X, L.L.C. | 10% owner | – | – | Sep 30, 2025 |
| James N. Topper | 10% owner | – | – | Sep 30, 2025 |
| Frazier Life Sciences X, L.P. | 10% owner | – | – | Sep 30, 2025 |
| Fhmls X, L.P. | 10% owner | 9,772,214 | 20.29% | Sep 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Salomon Azoulay Chief Medical Officer | Aug 4, 2026 | Sale | −370 | $65.77 | $24.33K | 14,399 |
| John W. Smither Chief Financial Officer | Aug 3, 2026 | Award | +28,000 | – | – | 28,000 |
| Steven L. Hoerter President and CEO, Director | Aug 3, 2026 | Award | +71,000 | – | – | 82,938 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Option exercise | +55,000 | $10.46 | $575.30K | 69,769 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −15,003 | $38.30 | $574.61K | 14,769 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Option exercise | +15,003 | $16.00 | $240.05K | 29,772 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −55,000 | $38.38 | $2.11M | 14,769 |
| P. Kent Hawryluk President & CEO, Director | May 6, 2026 | Sale | −607 | $29.54 | $17.93K | 727,667 |
| Salomon Azoulay Chief Medical Officer | May 6, 2026 | Sale | −231 | $29.54 | $6.82K | 14,769 |
| Steven L. Hoerter Director | May 1, 2026 | Award | +11,938 | – | – | 11,938 |
| P. Kent Hawryluk President & CEO, Director | Mar 13, 2026 | Buy | +18,500 | $28.41 | $525.59K | 486,777 |
| P. Kent Hawryluk President & CEO, Director | Feb 26, 2026 | Option exercise | +28,768 | $16.00 | $460.29K | 728,274 |
| Salomon Azoulay Chief Medical Officer | Feb 2, 2026 | Award | +15,000 | – | – | 15,000 |
| P. Kent Hawryluk President & CEO, Director | Feb 2, 2026 | Award | +35,250 | – | – | 699,506 |
| Richard Bartram Chief Financial Officer | Feb 2, 2026 | Award | +15,000 | – | – | 15,000 |
| P. Kent Hawryluk President & CEO, Director | Oct 24, 2025 | Option exercise | +182,859 | $3.25 | $594.29K | 664,256 |
| P. Kent Hawryluk President & CEO, Director | Oct 20, 2025 | Buy | +20,000 | $13.64 | $272.80K | 468,277 |
| Steven L. Hoerter Director | Oct 17, 2025 | Buy | +20,000 | $13.25 | $265.00K | 20,000 |
| Fhmls X, L.P. 10% owner | Sep 26, 2025 | Buy | +666,666 | $18.00 | $12.00M | 5,219,440 |
| Ora H. Pescovitz Director | Apr 8, 2025 | Buy | +7,693 | $5.89 | $45.31K | 24,329 |
| Carl L. Gordon Director, 10% owner | Feb 18, 2025 | Buy | +94,100 | $10.84 | $1.02M | 747,887 |
| Carl L. Gordon Director, 10% owner | Feb 18, 2025 | Buy | +49,070 | $10.84 | $531.92K | 3,255,000 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 18, 2025 | Buy | +49,070 | $10.84 | $531.92K | 3,255,000 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 18, 2025 | Buy | +94,100 | $10.84 | $1.02M | 747,887 |
| Carl L. Gordon Director, 10% owner | Feb 14, 2025 | Buy | +17,962 | $9.90 | $177.82K | 3,176,390 |
| Carl L. Gordon Director, 10% owner | Feb 14, 2025 | Buy | +29,540 | $9.85 | $290.97K | 3,205,930 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 14, 2025 | Buy | +29,540 | $9.85 | $290.97K | 3,205,930 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 14, 2025 | Buy | +17,962 | $9.90 | $177.82K | 3,176,390 |
| P. Kent Hawryluk President & CEO, Director | Feb 4, 2025 | Buy | +50,000 | $10.69 | $534.50K | 448,277 |
| Edward T. Mathers Director, 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Edward T. Mathers Director, 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Edward T. Mathers Director, 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Tiba Aynechi Director | Sep 16, 2024 | Conversion | +1,386,335 | – | – | 1,386,335 |
| Tiba Aynechi Director | Sep 16, 2024 | Buy | +750,000 | $16.00 | $12.00M | 2,136,335 |
| James M. Cornelius Director | Sep 16, 2024 | Conversion | +102,082 | – | – | 102,082 |
| Fhmls X, L.P. 10% owner | Sep 16, 2024 | Buy | +625,000 | $16.00 | $10.00M | 4,552,774 |
| Fhmls X, L.P. 10% owner | Sep 16, 2024 | Conversion | +3,927,774 | – | – | 3,927,774 |
| Forest Baskett 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Forest Baskett 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Forest Baskett 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Scott D. Sandell 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Scott D. Sandell 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Scott D. Sandell 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Paul Edward Walker 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Paul Edward Walker 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Paul Edward Walker 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| P. Kent Hawryluk President & CEO, Director | Sep 16, 2024 | Conversion | +115,914 | – | – | 398,277 |
| P. Kent Hawryluk President & CEO, Director | Sep 16, 2024 | Conversion | +283,846 | – | – | 481,397 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | Sep 16, 2024 | Conversion | +403,787 | – | – | 1,790,122 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | Sep 16, 2024 | Conversion | +1,386,335 | – | – | 1,386,335 |
| Rick Yang 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Rick Yang 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Rick Yang 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Buy | +250,000 | $16.00 | $4.00M | 653,787 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Conversion | +403,787 | – | – | 403,787 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,158,428 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Conversion | +2,658,428 | – | – | 2,658,428 |
| Anthony A. Florence Jr. 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Anthony A. Florence Jr. 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Anthony A. Florence Jr. 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| P. Kent Hawryluk Former Officer | Aug 17, 2026 | 3,745 | $255.74K | Aug 17, 2026 | Restricted Stock Vesting |
| Salomon Azoulay Officer | Aug 4, 2026 | 370 | $24.34K | Aug 4, 2026 | Restricted Stock Vesting |
| P. Kent Hawryluk Officer, Director | Aug 4, 2026 | 936 | $61.56K | Aug 4, 2026 | Restricted Stock Vesting |
| Richard Bartram Former Officer | Jun 10, 2026 | 9,167 | $280.01K | Jun 10, 2026 | Stock Option Exercise |
| Richard Bartram Former Officer | Jun 9, 2026 | 10,833 | $321.27K | Jun 9, 2026 | Stock Option Exercise |
| Richard Bartram Former Officer | May 13, 2026 | 15,000 | $554.30K | May 13, 2026 | Option Granted - 08/15/2023 |
| Richard Bartram Former Officer | May 11, 2026 | 22,500 | $991.90K | May 11, 2026 | Option Granted - 04/20/2022 |
| Salomon Azoulay Officer | May 8, 2026 | 70,003 | $2.69M | May 8, 2026 | Option Granted - 09/12/2024 |
| Richard Bartram Former Officer | May 8, 2026 | 10,000 | $379.56K | May 8, 2026 | Option Granted - 04/20/2022 |
| Richard Bartram Former Officer | May 7, 2026 | 10,000 | $322.05K | May 7, 2026 | Option Granted 04/20/2022 |
| Salomon Azoulay Officer | May 6, 2026 | 231 | $6.82K | May 6, 2026 | Restricted Stock Vesting |
| P. Kent Hawryluk Officer, Director | May 6, 2026 | 607 | $17.93K | May 6, 2026 | Restricted Stock Vesting |
| Richard Bartram Former Officer | May 1, 2026 | 5,000 | $159.00K | May 1, 2026 | Options Granted - 04/20/2022 |
| Richard Bartram Former Officer | Apr 22, 2026 | 10,423 | $341.38K | Apr 22, 2026 | Option Granted 04/20/2022 |
| Richard Bartram Former Officer | Mar 25, 2026 | 1,061 | $30.22K | Mar 25, 2026 | Restricted Stock Vesting |